Finance entity
markets is the sole category represented across all 1 tracked stories. AMT-130 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Last mentioned: Aug 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. AMT-130 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.7. We currently track 1 Finance story that mention Amylyx Pharmaceuticals, all published on August 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amylyx Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
A slate of upcoming catalysts could drive the next move for uniQure, CareDx, Adaptive Biotechnologies, Enliven Therapeutics, and Amylyx Pharmaceuticals, all of which posted big gains recently. uniQure's Q3 regulatory filing and September four-year data are key events.
Amylyx Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
